Ask AI
ProCE Banner Activity

Immunotherapy-Based Combinations in Intermediate HCC Eligible for TACE

Slideset

Download these slides from an ASCO 2025 live webinar on the use of immunotherapy-based combinations in intermediate HCC eligible for TACE, including expert-recommended best practices in HCC.

Released: May 28, 2025

Expiration: November 27, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Eisai and Merck Sharp & Dohme LLC.

Eisai

Merck Sharp & Dohme, LLC